Buy CJC-1295 no DAC Peptide America

What is CJC-1295 no DAC?

CJC-1295 no DAC is a peptide that stimulates the pituitary gland to boost growth hormone secretion, essential for growth, metabolism, and body composition. CJC-1295 no DAC is a Modified Growth Releasing Factor aminos 1-29, also known as Modified GRF (1-29).

While the natural form of GHRH has 44 amino acids, the truncated version called Sermorelin, or GRF 1-29, contains just 29 amino acids. Modified GRF (1-29) includes four substituted amino acids to enhance resistance against degradation and oxidation during production and in the body, also improving its binding affinity to GHRH receptors.

Mod GRF (1-29) is the portion of CJC-1295 DAC that is free from MPA, except for lysine. If lysine is present in a formulation labeled “CJC without DAC,” it shortens the peptide’s active lifespan, making it closer to Sermorelin in effect. Essentially, CJC no DAC is equivalent to Modified GRF (1-29) component.

CJC-1295 underwent further modification resulting in the addition of DAC (Drug Affinity Complex). This modification allows DAC to bind with a blood protein known as albumin, significantly extending its half-life to approximately eight days.

This peptide boosts growth hormone secretion similarly to others in its class but avoids common side effects like increased appetite and elevated cortisol, prolactin, acetylcholine, and aldosterone levels. This makes it an attractive choice for scientists seeking to optimize growth hormone production without unwanted hormonal fluctuations.

Buy CJC-1295 no DAC Nasal Spray, available in 15ml and 30ml glass spray bottles from Direct Peptides America.

CJC-1295 no DAC Mechanism Of Action

CJC-1295 No DAC operates primarily by mimicking the action of natural growth hormone-releasing hormone (GHRH), thereby facilitating the pulsatile release of growth hormone (GH) from the anterior pituitary gland.

This synthetic peptide binds to specific GHRH receptors located on the pituitary cells, triggering a cascade of intracellular signalling that leads to increased synthesis and secretion of GH. Elevated GH levels subsequently influence various physiological processes, including muscle growth, fat metabolism, and overall body composition.

The absence of the Drug Affinity Complex in CJC-1295 results in a shorter half-life, which allows researchers to investigate its acute effects on GH secretion and related metabolic pathways in a controlled manner. America Studies have demonstrated that this peptide can induce significant increases in serum GH levels, particularly when administered through subcutaneous injections.

Moreover, the regulation of GH secretion by CJC without Drug Affinity Complex is characterised by its ability to enhance the amplitude and frequency of GH pulses, clarifying its therapeutic potential in growth hormone deficient states and its role in optimising metabolic health. Understanding these mechanisms is crucial for future applications in research and clinical practice.